All Stories

  1. Grupo de Trabajo de la EFLM sobre Acreditación y Normas ISO/CEN sobre cómo abordar los requisitos de la norma ISO15189 sobre retención de documentación y muestras
  2. EFLM Working Group Accreditation and ISO/CEN standards on dealing with ISO 15189 demands for retention of documents and examination objects
  3. APS calculator: a data-driven tool for setting outcome-based analytical performance specifications for measurement uncertainty using specific clinical requirements and population data
  4. In-house diagnostic devices under the EU IVDR and unwanted side-effects of intentional transparency
  5. In reply to: Limitations in using the EFLM WG-A/ISO approach for assessment of reagent lot variability
  6. ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation
  7. M133 An approach for determining allowable between reagent lot variation
  8. An approach for determining allowable between reagent lot variation
  9. Improving the laboratory result release process in the light of ISO 15189:2012 standard
  10. Implementation of the new EU IVD regulation – urgent initiatives are needed to avert impending crisis
  11. Organisation and quality monitoring for point-of-care testing (POCT) in Belgium: proposal for an expansion of the legal framework for POCT into primary health care
  12. Validation and verification of examination procedures in medical laboratories: opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation
  13. Documenting metrological traceability as intended by ISO 15189:2012: A consensus statement about the practice of the implementation and auditing of this norm element
  14. Corrigendum to: Recommendation for the review of biological reference intervals in medical laboratories
  15. Monitoring glucose levels in critically ill patients
  16. Practical approach for medical validation of therapeutic drug monitoring results
  17. Accreditation process in European countries – an EFLM survey
  18. Recommendation for the review of biological reference intervals in medical laboratories
  19. Current Evidence and Future Perspectives on the Effective Practice of Patient-Centered Laboratory Medicine
  20. Flexible Scope for ISO15189 accreditation
  21. Practice-Oriented Quality Specifications for Therapeutic Drug Monitoring
  22. A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [iodogen] dissolved in dimethyl sulphoxide (DMSO)
  23. Performance of cassette-based blood gas analyzers to monitor blood glucose and lactate levels in a surgical intensive care setting
  24. Interference of ethylene glycol with lactate measurement: A comparison study on new generation cassette-based blood gas analyzers
  25. Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method
  26. Transient Catabolic State with Reduced IGF-I after Antenatal Glucocorticoids
  27. Model order selection for quantification of a multi-exponential magnetic resonance spectrum
  28. Fructosamine 3-kinase-related protein and deglycation in human erythrocytes
  29. Quantification of the glycogen13C-1 NMR signal during glycogen synthesis in perfused rat liver
  30. Proton magnetization transfer effect in rat liver lactate
  31. No-Flow Ischemia Inhibits Insulin Signaling in Heart by Decreasing Intracellular pH
  32. Conversion of a synthetic fructosamine into its 3-phospho derivative in human erythrocytes
  33. Conversion of a synthetic fructosamine into its 3-phospho derivative in human erythrocytes
  34. Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase.
  35. BAY R3401: A Blood-Glucose Lowering Prodrug's Impact on Phosphorylase a and b Activities
  36. Further observations on the uptake and effects of phosphonates in perfused rat liver studied by 31P‐NMR
  37. Further observations on the uptake and effects of phosphonates in perfused rat liver studied by31P-NMR
  38. On the inhibition of hepatic glycogenolysis by fructose. A31P-NMR study in perfused rat liver using the fructose analogue 2,5-anhydro-D-mannitol
  39. Phosphocreatine resynthesis is not affected by creatine loading
  40. 1H NMR spectroscopy study of the dynamic properties of glycogen in solution by steady-state magnetisation measurement with off-resonance irradiation
  41. Phosphonates as31P-NMR markers of extra- and intracellular space and pH in perfused rat liver
  42. Phosphonates as 31P‐NMR markers of extra- and intracellular space and pH in perfused rat liver
  43. Evaluation of signal processing methods for the quantification of a multi–exponential signal: the glycogen13C-1 NMR signal
  44. 13C-NMR relaxation in glycogen
  45. Modulation of basal hepatic glycogenolysis by nitric oxide
  46. Modulation of basal hepatic glycogenolysis by nitric oxide
  47. Caffeine counteracts the ergogenic action of muscle creatine loading
  48. Demonstration of a Glycogen/Glucose 1-Phosphate Cycle in Hepatocytes from Fasted Rats
  49. Evaluation of Signal Processing Methods for the Quantification of Strongly Overlapping Peaks in 31P NMR Spectra
  50. New Na(+)-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart.
  51. Ischaemic ATP degradation studied by HPLC and31P-NMR spectroscopy: do the two techniques observe the same ATP pools?
  52. In Situ13C NMR quantification of hepatic glycogen
  53. Bilirubin diglucuronide and monoglucuronides are formed at a single, lumenally oriented site of microsomal UDP-glucuronyltransferase
  54. Metabolic response to halothane in piglets susceptible to malignant hyperthermia: an in vivo 31P-NMR study
  55. Modulation of maximal glycogenolysis in perfused rat liver by adenosine and ATP
  56. 31P-NMR study of cardiac preservation: St. Thomas' Hospital cardioplegic solution versus UW preservation solution
  57. The cytosolic concentration of phosphate determines the maximal rate of glycogenolysis in perfused rat liver
  58. Double-tuned resonator designs for NMR spectroscopy
  59. Properties of membrane-bound bilirubin UDP-glucuronyltransferase in rough and smooth endoplasmic reticulum and in the nuclear envelope from rat liver
  60. Bile pigment metabolism
  61. Carrier-mediated translocation of uridine diphosphate glucose into the lumen of endoplasmic reticulum-derived vesicles from rat liver.
  62. Phosphate metabolites in rat skin
  63. Topology and regulation of bilirubin UDP-glucuronyltransferase in sealed native microsomes from rat liver
  64. Phosphate metabolites in rat skin
  65. On the binding of bilirubin and its structural analogs to hepatic microsomal bilirubin UDPglucuronyltransferase
  66. Endogenous esterification of bilirubin by liver microsomes. Evidence for an intramicrosomal pool of UDP-glucose and lumenal orientation of bilirubin UDP-glycosyltransferase.
  67. Assay of mannose-6-phosphatase in untreated and detergent-disrupted rat-liver microsomes for assessment of integrity of microsomal preparations
  68. Radioassay of UDP-glucuronyltransferase-catalysed formation of bilirubin monoglucuronides and bilirubin diglucuronide in liver microsomes
  69. Free Ionised Calcium—A Critical Survey
  70. Induction of hepatic glycogen synthesis by glucocorticoids is not mediated by insulin
  71. The role of glycogen synthase phosphatase in the glucocorticoid-induced deposition of glycogen in foetal rat liver
  72. Glycogen-Synthase Phosphatase Activity in Rat Liver. Two Protein Components and Their Requirement for the Activation of Different Types of Substrate